Search results
Genentech's legacy and future aspirations are built on the belief that the boundaries of science are meant to be broken and that we can solve some of the hardest biomedical challenges plaguing humankind. Learn More. Quick Links. Advancing Inclusive Research. Patient Financial Support.
Archived from the original on April 18, 2012. Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech.
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
Genentech is a leading biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Its transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
WHY GENENTECH. We’re passionate about delivering on Our Promise to improve the lives of patients and create healthier communities for all. We foster a culture of inclusivity, integrity and creativity while boldly pursuing answers to the world’s most complex health challenges and transforming society.
Genentech has multiple medicines for serious and life-threatening medical conditions. Access information and resources on each of our medicines.
Genentech | 750,102 followers on LinkedIn. About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions.
Genentech is committed to defeating cancer. Building upon our legacy as pioneers in oncology, we're boldly innovating beyond the science and envision a better future for every cancer patient, caregiver, and provider. We can't do it alone.
Learn how Genentech is continuing to go forward in the precision medicine space with real-world evidence, education for policymakers, development of molecules, education on biomarker testing and more.
We would like to show you a description here but the site won’t allow us.
